Identification of biomarkers regulated by rexinoids (LGD1069, LG100268 and Ro25-7386) in human breast cells using Affymetrix microarray

Seo,Hye‑Sook; Woo,Jong‑Kyu; Shin,Yong  Cheol; Ko,Seong‑Gyu

doi:10.3892/mmr.2015.3480

Identification of biomarkers regulated by rexinoids (LGD1069, LG100268 and Ro25-7386) in human breast cells using Affymetrix microarray

Authors:
- Hye‑Sook Seo
- Jong‑Kyu Woo
- Yong Cheol Shin
- Seong‑Gyu Ko
View Affiliations

Affiliations: Laboratory of Clinical Biology and Pharmacogenomics and Center for Clinical Research and Genomics, College of Korean Medicine, Kyung Hee University, Dongdaemun‑gu, Seoul 130‑701, Republic of Korea, Laboratory of Preventive Pharmacy, College of Pharmacy, Gachon University of Medicine and Science, Yeonsu‑gu, Incheon 406‑840, Republic of Korea
Published online on: March 12, 2015 https://doi.org/10.3892/mmr.2015.3480
Pages: 800-818
Copyright: © Seo et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Retinoids possess anti‑proliferative properties, which suggests that they possess chemopreventive and therapeutic potential against cancer. In the current study, genes modulated by rexinoids (retinoid X receptor (RXR)‑pan agonists, LGD1069 and LG100268; and the RXRα agonist, Ro25‑7386) were identified using an Affymetrix microarray in normal and malignant breast cells. It was observed that LGD1069, LG100268 and Ro25‑7386 suppressed the growth of breast cells. Secondly, several rexinoid‑regulated genes were identified, which are involved in cell death, cell growth/maintenance, signal transduction and response to stimulus. These genes may be associated with the growth‑suppressive activity of rexinoids. Therefore, the identified genes may serve as biomarkers and novel molecular targets for the prevention and treatment of breast cancer.

View Figures

View References

1	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
2	DeSantis C, Ma J, Bryan L and Jemal A: Breast cancer statistics, 2013. CA Cancer J Clin. 64:52–62. 2014. View Article : Google Scholar
3	Abu J, Batuwangala M, Herbert K and Symonds P: Retinoic acid and retinoid receptors: potential chemopreventive and therapeutic role in cervical cancer. Lancet Oncol. 6:712–720. 2005. View Article : Google Scholar : PubMed/NCBI
4	De Luca LM, Darwiche N, Celli G, Kosa K, Jones C, Ross S and Chen LC: Vitamin A in epithelial differentiation and skin carcinogenesis. Nutr Rev. 52:S45–S52. 1994. View Article : Google Scholar : PubMed/NCBI
5	Gudas LJ, Sporn MB and Roberts AB: Cellular biology and biochemistry of the retinoids. The Retinoids: Biology, Chemistry and Medicine. Sporn MB, Roberts AB and Goodman DS: Raven Press, Ltd; New York: pp. 443–520. 1994
6	Niles RM: Recent advances in the use of vitamin A (retinoids) in the prevention and treatment of cancer. Nutrition. 16:1084–1089. 2000. View Article : Google Scholar : PubMed/NCBI
7	Simeone AM and Tari AM: How retinoids regulate breast cancer cell proliferation and apoptosis. Cell Mol Life Sci. 61:1475–1484. 2004. View Article : Google Scholar : PubMed/NCBI
8	Love JM and Gudas LJ: Vitamin A, differentiation and cancer. Curr Opin Cell Biol. 6:825–831. 1994. View Article : Google Scholar : PubMed/NCBI
9	Vivat-Hannah V, You D, Rizzo C, Daris JP, Lapointe P, Zusi FC, Marinier A, Lorenzi MV and Gottardis MM: Synergistic cytotoxicity exhibited by combination treatment of selective retinoid ligands with taxol (Paclitaxel). Cancer Res. 61:8703–8711. 2001.PubMed/NCBI
10	Altucci L, Rossin A, Raffelsberger W, Reitmair A, Chomienne C and Gronemeyer H: Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat Med. 7:680–686. 2001. View Article : Google Scholar : PubMed/NCBI
11	Chambon P: A decade of molecular biology of retinoic acid receptors. FASEB J. 10:940–954. 1996.PubMed/NCBI
12	Giguère V: Retinoic acid receptors and cellular retinoid binding proteins: Complex interplay in retinoid signaling. Endocr Rev. 15:61–79. 1994.PubMed/NCBI
13	Zusi FC, Lorenzi MV and Vivat-Hannah V: Selective retinoids and rexinoids in cancer therapy and chemoprevention. Drug Discov Today. 7:1165–1174. 2002. View Article : Google Scholar
14	Thacher SM, Vasudevan J and Chandraratna RA: Therapeutic applications for ligands of retinoid receptors. Curr Pharm Des. 6:25–58. 2000. View Article : Google Scholar : PubMed/NCBI
15	Nagpal S and Chandraratna RA: Recent developments in receptor-selective retinoids. Curr Pharm Des. 6:919–931. 2000. View Article : Google Scholar : PubMed/NCBI
16	Kong G, Kim HT, Wu K, et al: The retinoid X receptor-selective retinoid, LGD1069, downregulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention. Cancer Res. 65:3462–3469. 2005.PubMed/NCBI
17	Nagy L, Thomazy VA, Heyman RA and Davies PJ: Retinoid-induced apoptosis in normal and neoplastic tissues. Cell Death Differ. 5:11–19. 1998. View Article : Google Scholar
18	Lippman SM and Lotan R: Advances in the development of retinoids as chemopreventive agents. J Nutr. 130(Suppl 2): 479S–482S. 2000.PubMed/NCBI
19	Gottardis MM, Bischoff ED, Shirley MA, Wagoner MA, Lamph WW and Heyman RA: Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res. 56:5566–5570. 1996.PubMed/NCBI
20	Wu K, Zhang Y, Xu XC, et al: The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res. 62:6376–6380. 2002.PubMed/NCBI
21	Wu K, Kim HT, Rodriquez JL, et al: Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol Biomarkers Prev. 11:467–474. 2002.PubMed/NCBI
22	Crowe DL and Chandraratna RA: A retinoid X receptor (RXR)-selective retinoid reveals that RXR-alpha is potentially a therapeutic target in breast cancer cell lines and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands. Breast Cancer Res. 6:R546–R555. 2004. View Article : Google Scholar
23	Farol LT and Hymes KB: Bexarotene: a clinical review. Expert Rev Anticancer Ther. 4:180–188. 2004. View Article : Google Scholar : PubMed/NCBI
24	Rigas JR and Dragnev KH: Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene. Oncologist. 10:22–33. 2005. View Article : Google Scholar : PubMed/NCBI
25	Ma Y, Koza-Taylor PH, DiMattia DA, Hames L, Fu H, Dragnev KH, Turi T, Beebe JS, Freemantle SJ and Dmitrovsky E: Microarray analysis uncovers retinoid targets in human bronchial epithelial cells. Oncogene. 22:4924–4932. 2003. View Article : Google Scholar : PubMed/NCBI
26	Li G, Walch E, Yang X, Lippman SM and Clifford JL: Cloning and characterization of the human retinoid X receptor alpha gene: conservation of structure with the mouse homolog. Biochem Biophys Res Commun. 69:54–57. 2000. View Article : Google Scholar